Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery

NEW YORK, March 26, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced the deployment of OpenClaw™, an advanced AI-enabled computational platform designed to accelerate drug discovery, enhance data-driven decision-making, and unlock value across its therapeutic pipeline. OpenClaw™ Activation Marks Strategic Shift Toward AI-Driven Drug Development The launch of OpenClaw™ establishes a centralized, high-performance platform capable of integrating preclinical and clinical datasets in real time, enabling faster and more efficient research execution.